Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 473-482

  Maasoumy, Benjamin ^a   Vermehren, Johannes ^b   Welker, Martin Walter ^b   Bremer, Birgit ^a   Perner, Dany ^b   Höner zu Siederdissen, Christoph ^a   Deterding, Katja ^a   Lehmann, Patrick ^a   Cloherty, Gavin ^c   Reinhardt, Birgit ^d   Pawlotsky, Jean Michel ^e   Manns, Michael P ^a   Zeuzem, Stefan ^b   Cornberg, Markus ^a   Wedemeyer, Heiner ^a   Sarrazin, Christoph ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Abbott Molecular Inc   (United States)

^d ABBOTT GMBH AND CO KG   (Germany)

^e HENRI MONDOR HOSPITAL   (France)

Author keywords

Direct acting antivirals; HCV RNA; HCV RNA assays; HCV RNA kinetics; HCV RNA quantification; Hepatitis C; Relapse; Response predictors; Sofosbuvir; Sustained virological response

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; GENOTYPE; HEPACIVIRUS; RNA VIRUS;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; RNA VIRUSES; SIMEPREVIR; SOFOSBUVIR;

EID: 84977652640     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.04.006     Document Type: Article

References (37)

1. [1] Maasoumy, B., Wedemeyer, H., Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26 (2012), 401–412.
2. [2] European, Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on-Treatment of Hepatitis C 2015. J Hepatol. 2015.
3. [3] Pawlotsky, J.M., Feld, J.J., Zeuzem, S., Hoofnagle, J.H., From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62 (2015), S87–S99.
4. [4] Feld, J.J., The beginning of the end: what is the future of interferon therapy for chronic hepatitis C. Antiviral Res 105 (2014), 32–38.
5. [5] Manns, M.P., Wedemeyer, H., Cornberg, M., Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 (2006), 1350–1359.
6. [6] Kau, A., Vermehren, J., Sarrazin, C., Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 49 (2008), 634–651.
7. [7] Chevaliez, S., Pawlotsky, J.M., How to use virological tools for optimal management of chronic hepatitis C. Liver Int 29 (2009), 9–14.
8. [8] Maasoumy, B., Manns, M.P., Optimal treatment with boceprevir for chronic HCV infection. Liver Int 33 (2013), 14–22.
9. [9] Jesudian, A.B., Jacobson, I.M., Optimal treatment with telaprevir for chronic HCV infection. Liver Int 33 (2013), 3–13.
10. [10] Svarovskaia, E.S., Dvory-Sobol, H., Parkin, N., Hebner, C., Gontcharova, V., Martin, R., et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 59 (2014), 1666–1674.
11. [11] Feld, J.J., Interferon-free strategies with a nucleoside/nucleotide analogue. Semin Liver Dis 34 (2014), 37–46.
12. [12] Koff, R.S., Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 39 (2014), 478–487.
13. [13] Pawlotsky, J.M., New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146 (2014), 1176–1192.
14. [14] Vermehren, J., Yu, M.L., Monto, A., Yao, J.D., Anderson, C., Bertuzis, R., et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 52 (2011), 133–137.
15. [15] Zitzer, H., Heilek, G., Truchon, K., Susser, S., Vermehren, J., Sizmann, D., et al. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol 51 (2013), 571–577.
16. [16] Castéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005), 343–350.
17. [17] Martí-Bonmatí, L., Delgado, F., MR imaging in liver cirrhosis: classical and new approaches. Insights Imaging 1 (2010), 233–244.
18. [18] Yoshida, E.M., Sulkowski, M.S., Gane, E.J., Herring, R.W., Ratziu, V., Ding, X., et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 61 (2015), 41–45.
19. [19] Wyles, D.L., Nelson, D.R., Swain, M.G., Gish, R.G., Ma, J., McNally, J., et al. On treatment HCV RNA as a predictor of virologic response in sofosbuvir-containing regimens for genotype 2/3 HCV infection: Analysis of the FISSION, POSITRON, and FUSION studies. Hepatology, 58, 2013, 140A.
20. [20] Jacobson, I.M., Gordon, S.C., Kowdley, K.V., Yoshida, E.M., Rodriguez-Torres, M., Sulkowski, M.S., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368 (2013), 1867–1877.
21. [21] Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
22. [22] Zeuzem, S., Dusheiko, G.M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R.H., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370 (2014), 1993–2001.
23. [23] Vermehren, J., Aghemo, A., Falconer, K., Susser, S., Lunghi, G., Zeuzem, S., et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J Hepatol 60 (2014), 913–919, 10.1016/j.jhep.2014.01.002.
24. [24] Maasoumy, B., Cobb, B., Bremer, B., Luk, K., Halfon, P., Aslam, S., et al. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther 39 (2014), 85–92.
25. [25] Fevery, B., Susser, S., Lenz, O., Cloherty, G., Perner, D., Picchio, G., et al. HCV RNA quantification with different assays: implications for protease inhibitor-based response-guided therapy. Antivir Ther 19 (2014), 559–567, 10.3851/IMP2760.
26. [26] Kessler, H.H., Cobb, B.R., Wedemeyer, H., Maasoumy, B., Michel-Treil, V., Ceccherini-Nelli, L., et al. Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. J Clin Virol 67 (2015), 67–72.
27. [27] Sarrazin, C., Wedemeyer, H., Cloherty, G., Cohen, D.E., Chevaliez, S., Herman, C., et al. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. J Virol Methods 214 (2015), 29–32.
28. [28] Sidharthan, S., Kohli, A., Sims, Z., Nelson, A., Osinusi, A., Masur, H., et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis 60 (2015), 1743–1751.
29. [29] Heim, M.H., Thimme, R., Innate and adaptive immune responses in HCV infections. J Hepatol 61 (2014), S14–S25.
30. [30] Meissner, E.G., Wu, D., Osinusi, A., Bon, D., Virtaneva, K., Sturdevant, D., et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124 (2014), 3352–3363.
31. [31] Martin, B., Hennecke, N., Lohmann, V., Kayser, A., Neumann-Haefelin, C., Kukolj, G., et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 61 (2014), 538–543.
32. [32] Zignego, A.L., Macchia, D., Monti, M., Thiers, V., Mazzetti, M., Foschi, M., et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 15 (1992), 382–386.
33. [33] Ferri, C., Monti, M., La Civita, L., Longombardo, G., Greco, F., Pasero, G., et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 82 (1993), 3701–3704.
34. [34] Diseases AAFTSOL, America IDSO. Recommendations for testing, managing, and treating hepatitis C; 2014.
35. [35] Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., Gitlin, N., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
36. [36] Leroy V, Angus P, Bronowicki JP, Dore G, Hézode C, Pianko S et al. All-oral treatment with daclatasvir plus sofosbuvir plus ribavirin for 12 or 16 weeks in HCV genotype 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco, CA; 2015.
37. [37] Foster, G.R., Pianko, S., Brown, A., Forton, D., Nahass, R.G., George, J., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.